Search
Ceritinib
go.drugbank.com/drugs/DB09063ApprovedInvestigationalcarcinogenesis and seems to drive the malignant phenotype. … This occurrence led to development of novel second-generation ALK inhibitors such as ceritinib to overcome crizotinib resistance.
Pegaspargase
go.drugbank.com/drugs/DB00059ApprovedInvestigationalThe pegylation of pegaspargase allows access to the enzyme's active sites while limiting reticuloendothelial system uptake and reducing immune detection, and it also increases the half-life of L-asparaginase … [A255912,A255917] In February 1994, pegaspargase was approved by the FDA for the treatment of ALL in patients with hypersensitivity to native forms of L-asparaginase.[A255927]
Desogestrel
go.drugbank.com/drugs/DB00304ApprovedInvestigationalDesogestrel, a prodrug, is a third generation progestogen[A176315] and hence, a member of the gonane family which was largely used in Europe before being approved in the US and Canada. … [F4127] In the US, desogestrel is found only in combination with [ethinyl estradiol].
Mixtures: DESOGESTREL E ETINILESTRADIOLO ARISTO, DESOGESTREL E ETINILESTRADIOLO ARISTOCategories: Sex Hormones and Modulators of the Genital SystemEbola Zaire vaccine (live, attenuated)
go.drugbank.com/drugs/DB15595ApprovedInvestigational[L10854] By introducing the relatively inactive viral protein to the patient, the patient’s immune system learns to recognize and attack the virus if he or she is exposed to it in the future. … to as the Democratic Republic of the Congo) and Sudan.
Synonyms: Recombinant Vesicular Stomatitis Virus (rVSV) strain Indiana with a deletion of the VSV envelope glycoprotein (G) replaced with the Zaire Ebola Virus (ZEBOV) Kikwit 1995 strain surface glycoprotein (GPCanakinumab
go.drugbank.com/drugs/DB06168ApprovedInvestigationalClinical trials have established the administration of canakinumab every 2 weeks to be safe and effective, offering a considerable advantage over the existing treatment with the human IL-1 receptor antagonist … Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass.
Elotuzumab
go.drugbank.com/drugs/DB06317ApprovedInvestigationalone to three prior therapies. … Elotuzumab has a theoretical mass of 148.1 kDa for the intact antibody. Elotuzumab was approved on November 30, 2015 by the U.S. Food and Drug Administration.
Octreotide
go.drugbank.com/drugs/DB00104ApprovedInvestigationalOn June 26, 2020, the first approved delayed-release oral somatostatin analog, Mycapssa, received FDA approval for the long term maintenance treatment of acromegaly. … [L14501] Octreotide is a long-acting drug with pharmacologic activities that mimic those of the natural hormone, somatostatin, which inhibits the secretion of growth hormone.
Products: SANDOSTATIN LAR 10 MG ENJEKSİYONLUK SÜSPANSİYON İÇİN TOZ VE ÇÖZÜCÜ, 1 ADET, SANDOSTATIN LAR 20 MG ENJEKSİYONLUK SÜSPANSİYON İÇİN TOZ VE ÇÖZÜCÜ, 1 ADETImlifidase
go.drugbank.com/drugs/DB15258ApprovedInvestigationalto non-self HLA antigens, face additional barriers to transplantation. … [L28001] As a result, the risk of antibody-mediated rejection is reduced allowing kidney transplantation in highly sensitized patients to proceed.[A225836,L28001]
Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB10788ApprovedInvestigationalBordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) is a vaccine that contains inactivated acellular pertussis antigen that is isolated from Bordetella pertussis culture.
Mixtures: INFANRIX (TM) - IPV, PENTAXİM 0,5 ML IM ENJEKSİYONLUK SÜSPANSİYON İÇİN TOZ İÇEREN FLAKON VE SÜSPANSİYON İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADETRosiglitazone
go.drugbank.com/drugs/DB00412ApprovedInvestigationalRecent research has suggested that rosiglitazone may also be of benefit to a subset of patients with Alzheimer's disease not expressing the ApoE4 allele. … Like other thiazolidinediones, the mechanism of action of rosiglitazone is by activation of the intracellular receptor class of the peroxisome proliferator-activated receptors (PPARs), specifically PPARγ